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CARDIOLOGY

Case Report: Diagnosis of Dual-Biopsy Negative
Severe Cardiac Amyloidosis
Kristin Lohr, MD and Eric Kasprowicz, MD

INTRODUCTION
Amyloidosis is a rare disorder that involves the deposition
of misfolded protein in extracellular tissue. Disease
manifestations vary depending on the affected organs.
Areas most often involved include the kidneys, gastrointestinal tract, heart, nervous system, and musculoskeletal
system. The most common type is AL amyloidosis, in
which plasma cells produce an abundance of a
monoclonal proteins that affect numerous organ systems.
A second variety, AA amyloidosis, is associated with
inflammatory diseases such as rheumatoid arthritis and
inflammatory bowel disease. Finally, a heritable version of
amyloidosis mediated by mutations in the transthyretin
protein (TTR) has a predilection for deposition in peripheral
nerves and cardiac tissue1.

CASE PRESENTATION
A 72 year-old female with a history of non-ischemic
cardiomyopathy (NICM) with an ejection fraction (EF) of
30-35%, monoclonal gammopathy of undetermined
significance (MGUS), and chronic kidney disease (CKD)
Stage 4 presented to the ED with several weeks of
intermittent dizziness, nausea with dry heaving,
intermittent shortness of breath, and pleuritic chest pain.
At the time of admission she denied exertional chest
pain, lower extremity swelling, or recent weight gain.
She endorsed stable four-pillow orthopnea, good urine
output in response to her home dose of bumetanide,
and adherence to all her medications as well as to a
low salt diet.

Figure 1. Cardiac MRI
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The patient was diagnosed with NICM in 2013 after
presenting with rapidly progressive dyspnea on exertion,
new lower extremity swelling, and five-pillow orthopnea.
A CT of her thorax at that time showed hilar lymphaden o p a t h y, a n d t r a n s t h o r a c i c e c h o c a r d i o g r a m
demonstrated an EF of 30%, decreased from 45% in
2012. A cardiac catheterization in 2012 revealed no
coronary artery disease, and, given her new hilar
lymphadenopathy on imaging, an infiltrative process
such as sarcoidosis or amyloidosis was suspected as a
possible cause for her worsening heart failure. She
underwent a fat pad biopsy at the time which was
negative for amyloidosis. To follow, a cardiac MRI
revealed no definitive evidence of sarcoidosis or
amyloidosis. Furthermore, the patchy, delayed
mid-myocardial enhancement in the left ventricle was
attributed to viral myocarditis and thus the likely cause
for her new onset heart failure (Figure 1). After diagnosis,
the patient’s EF recovered to 65% with aggressive
management, but declined again to 30-35% despite
optimal therapy. Transthoracic echocardiogram from
this admission demonstrated an ejection fraction of
35%, biventricular hypertrophy with a restrictive pattern,
and biatrial enlargement (Figure 2).
Other relevant medical history includes an ablation for
atrial tachycardia six months prior to this admission. She
also had a history of Protein S Deficiency complicated
by pulmonary embolism requiring anticoagulation on
warfarin.

Figure 2. Four-chamber view of the patient’s echocardiogram, displaying ventricular
wall thickening and granular appearing myocardium.
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Figure 3. Electrocardiogram findings from our patient demonstrating low voltage in
the limb leads and 1st degree AV block

Physical examination on admission revealed normal
vital signs, lungs clear to auscultation with no crackles,
cardiac exam with normal S1/S2 sounds, a tachycardic
rate with regular rhythm and no murmurs, rubs, or
gallops. Pulses were normal and JVD was not present.
Extremities were warm, well perfused and without any
peripheral edema. Labs were significant for a troponin
elevation to 0.21 ng/mL (baseline 0.15 ng/mL) and
pro-brain natriuretic peptide (pro-BNP) elevated to
10,358 pg/mL compared to 4,700 pg/mL at her last
admission 6 months earlier. EKG showed normal sinus
rhythm with first-degree AV block and low voltage
(Figure 3), and chest x-ray showed no consolidations
or pulmonary edema.

DIFFERENTIAL DIAGNOSIS
The patient’s presenting symptoms were attributed to
an exacerbation of her chronic systolic heart failure,
and she was admitted for diuresis and further
management. Despite this initial assessment and her
elevated pro-BNP, she appeared euvolemic on
subsequent examination with no elevation of jugular
venous pressure, no peripheral edema, and clear lungs.
With this ambiguous clinical picture, a right heart
catheterization was performed to assess her
hemodynamics. The catheterization revealed a
pulmonary capillary wedge pressure of 15 mm Hg, right
atrial pressure of 18 mm Hg, and cardiac index of 1.6 L/
min/m2 consistent with low output heart failure.
Despite her negative fat pad biopsy in the past, other
clinical data (echocardiogram, EKG, past medical
history, and physical examination) supported a diagnosis
of amyloidosis. Given the continued suspicion, an
endomyocardial biopsy was performed at the time of
her right heart catheterization and stained positive for
Congo Red, consistent with a diagnosis of amyloidosis
(Figure 4). Further typing by mass spectrometry was
performed at the Mayo Clinic Laboratory which showed
hereditary ATTR amyloidosis with a Val122Ile mutation.
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Figure 4. Endomyocardial biopsy slides from this case stained with Congo Red. (A)
In this figure the normal myocardium is off-white, and the areas of amyloid deposition
are salmon-colored (Congo red stain; Bright field microscopy, 10X magnification).
(B) Demonstrates Congo-red staining under a polarized filter. In this figure, normal
myocardium appears blue, collagen (fibrosis) is white, and amyloid deposits are
yellow-green (Congo red stain; Polarized light microscopy, 10X magnification).

OUTCOME AND FOLLOW-UP
The patient continues to follow up with Cardiology,
Nephrology and Hematology/Oncology for management
of her cardiac amyloidosis. She has remained stable on
her medication regimen since discharge. Further
management decisions regarding her amyloidosis were
deferred at time of discharge to await the results of mass
spectrometry. Unfortunately, ATTR amyloidosis does not
respond to chemotherapy as AL amyloidosis may, and
supportive care is the only management in cases
ineligible for transplant2. Typically, liver transplantation is
used to remove the culprit organ for abnormal TTR
synthesis, and heart transplant may be used in
management of end stage heart failure secondary to
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cardiac amyloid2,3. Given her advanced age and need for
combined liver-heart transplantation, she is not a
candidate for these traditional therapies but may be
eligible for clinical trials of small molecular inhibitors for
ATTR amyloid4.

DISCUSSION
The diagnosis of cardiac amyloid is suggested by
increased ventricular wall thickness and granular
appearance of myocardium on echocardiogram
(Figure 2) as well as low voltage on EKG (Figure 3).
Tachyarrhythmias and prolonged PR and QT intervals
are also often associated with cardiac amyloidosis, both
of which were present in this patient. As mentioned
above, the patient had first-degree A/V block and a
prolonged QT interval on admission (Figure 3), in
addition to recent ablation for atrial tachycardia.
Cardiac MRI is helpful in identifying cardiac amyloidosis
but is not very sensitive in the early stages of the disease2.
This was likely the case in our patient, as the MRI was
performed around the time of the patient’s initial
presentation of heart failure. The gold standard for
diagnosis is endomyocardial biopsy (Figure 3), but this is
not typically a first line diagnostic tool given the ease of
obtaining biopsy samples from other sites, such as the
abdominal fat pad or bone marrow. Interestingly,
abdominal fat pad and bone marrow biopsies will only
verify the diagnosis of amyloidosis in 40-80% of cases5.
This is particularly true in the Val122Ile mutation seen in
our patient, where amyloid deposition is primarily
confined to the heart2.
Cardiac amyloidosis is among the most serious manifestations of amyloidosis and is associated with poor
prognosis and high mortality. Median survival from
diagnosis of this variant of ATTR amyloidosis is
approximately 2-3 years1. Once the diagnosis is made,
management centers around supportive care and
medical management of heart failure symptoms.
Additionally, the underlying protein misfolding disorder
should be treated, if possible, with chemotherapy in the
case of AL amyloid and with liver transplant in the case
of ATTR amyloid1. As mentioned above, these patients
are sometimes evaluated for dual liver-heart transplantation depending on the severity of their disease3.
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KEY POINTS
This case illustrates a presentation of cardiac amyloid
with many classic diagnostic findings. These include:
EKG findings of first degree A/V block and low-voltage
complexes, atrial tachyarrhythmia, and elevated pro-BNP
without clear signs of overt volume overload.
Unfortunately for this patient, her prognosis remains
poor, but the case illustrates an important point - in cases
of progressive non-ischemic heart failure with an unclear
etiology, it is important to keep a broad differential and
consider cardiac amyloid if clinical signs point toward the
diagnosis. Biopsies from non-cardiac tissue can provide
important diagnostic information, possibly confirming
the disease, but lack the sensitivity needed to completely
rule out the disorder. Endomyocardial biopsy remains
the gold standard for diagnosis of cardiac amyloid and
should be pursued if clinical suspicion for the disease
remains high.
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